Does Geisinger Health Plan Cover Cialis?

What Is Geisinger Health Plan and How Does Its Formulary Work?

Geisinger Health Plan is a regional managed-care organization headquartered in Danville, Pennsylvania, serving members across Pennsylvania and New Jersey. The plan operates commercial, Medicare Advantage, and Medicaid managed-care lines of business, each governed by a separate formulary. A formulary is a tiered list of covered drugs; the tier a drug lands on determines your copay or coinsurance.

Plan Types and Their Formulary Differences

Geisinger offers several distinct plan products. Commercial HMO and PPO plans use a five-tier or six-tier formulary. Medicare Advantage plans follow CMS Part D rules, which classify drugs into tiers 1 through 5 and impose their own coverage requirements. Medicaid managed-care plans follow Pennsylvania Department of Human Services preferred drug list (PDL) rules.

Each product year, Geisinger's Pharmacy and Therapeutics (P&T) Committee reviews clinical evidence and pricing to place drugs on the formulary. The FDA-approved labeling for tadalafil covers three distinct conditions, and the indication submitted on the prescription claim affects which formulary category applies. The FDA notes that tadalafil 5 mg once daily is separately approved for both ED and BPH, which is clinically relevant because BPH claims may face less scrutiny on coverage reviews than ED claims alone [1].

Why the Diagnosis Code Matters

Insurance carriers, including Geisinger, process pharmacy claims alongside the medical diagnosis code (ICD-10) on the corresponding office visit. For ED, the standard code is N52.9 (male erectile dysfunction, unspecified). For BPH, the code is N40.1 (enlarged prostate with lower urinary tract symptoms). Plans that exclude ED drugs as a benefit category may still cover tadalafil 5 mg daily when the primary diagnosis is BPH. Submitting both codes when clinically accurate is legal and appropriate; your prescriber makes that determination based on documented symptoms.

Is Cialis Specifically Covered by Geisinger Health Plan?

Brand-name Cialis is frequently placed on a high formulary tier or excluded outright on commercial plans. Generic tadalafil, which the FDA approved as bioequivalent to Cialis, is the more reliably covered option. Coverage specifics change each plan year, so the only definitive answer requires checking your current Evidence of Coverage (EOC) document or calling the member services number on your insurance card.

Brand Cialis vs. Generic Tadalafil

The FDA granted first generic approval for tadalafil in September 2018 [2]. Since then, generic tadalafil has become widely available at a fraction of the brand cost. Most commercial formularies now place brand Cialis on Tier 4 or Tier 5 (specialty or non-preferred brand), while generic tadalafil sits on Tier 2 (preferred generic) or Tier 3 (non-preferred generic).

A 2023 JAMA Internal Medicine analysis found that out-of-pocket costs for erectile dysfunction medications dropped by a median of 78% after generic entry [3]. That cost shift reflects exactly the formulary dynamic Geisinger members now encounter: brand Cialis is rarely the cost-effective path.

Prior Authorization Requirements

Prior authorization (PA) for brand Cialis is common across managed-care plans. For generic tadalafil prescribed for ED, PA requirements vary by plan tier and diagnosis. For the BPH indication at the 5 mg daily dose, PA is less frequently required because BPH is not classified as a lifestyle condition by most state benefit mandates.

If PA is required, your prescribing clinician submits clinical documentation showing:

• Confirmed diagnosis with ICD-10 code
• Failure of or contraindication to a formulary-preferred alternative (often sildenafil)
• Absence of contraindications such as concurrent nitrate use

The FDA drug label for tadalafil explicitly contraindicates concurrent nitrate administration due to the risk of severe hypotension [4].

Step Therapy and Sildenafil-First Policies

Many Geisinger commercial plans require step therapy, meaning you must try and document a therapeutic failure with sildenafil (generic Viagra) before tadalafil is approved. Sildenafil is a short-acting PDE5 inhibitor taken 30 to 60 minutes before sexual activity; tadalafil has a half-life of approximately 17.5 hours, permitting once-daily dosing or on-demand use up to 36 hours after ingestion [5]. Patients who prefer spontaneous timing or who experience sildenafil side effects (flushing, visual disturbance, headache) have a documented clinical rationale for requesting tadalafil instead.

The Clinical Evidence Behind Tadalafil for ED and BPH

Understanding the clinical evidence helps you and your prescriber build a stronger prior authorization argument if needed.

Tadalafil Efficacy in Erectile Dysfunction

The key Phase 3 trials submitted to the FDA demonstrated that tadalafil 20 mg on demand produced successful intercourse rates of 75% compared with 32% for placebo in men with ED of mixed etiology [6]. The International Index of Erectile Function (IIEF) erectile function domain score improved by a mean of 7.0 points over placebo, a clinically meaningful threshold the field widely accepts.

A Cochrane systematic review of PDE5 inhibitors covering 82 randomized controlled trials (N=20,896) confirmed that all approved PDE5 inhibitors produce statistically significant improvements in IIEF scores (P<0.001) with acceptable safety profiles [7]. Tadalafil showed a favorable duration-of-action profile not seen with sildenafil or vardenafil, which may influence patient preference and treatment adherence.

Tadalafil Efficacy in BPH

The FDA's 2011 approval of tadalafil 5 mg once daily for BPH was based on four placebo-controlled trials. Across those trials, tadalafil reduced the International Prostate Symptom Score (IPSS) by a mean of 2.8 to 3.8 points versus 0.4 to 1.7 for placebo [8]. This effect size is clinically comparable to some alpha-blockers in mild-to-moderate BPH.

The AUA Guideline on BPH (2021 update) acknowledges PDE5 inhibitors as an evidence-based option for men with BPH and concomitant ED [9]. That guideline language gives prescribers a credentialed basis for submitting tadalafil as a medically necessary treatment rather than a lifestyle drug.

Cardiovascular Safety Considerations

Men with ED frequently have underlying cardiovascular disease. A 2018 BMJ meta-analysis of 18 randomized trials found no significant increase in major adverse cardiovascular events (MACE) with PDE5 inhibitor use compared to placebo (risk ratio 0.82, 95% CI 0.61 to 1.11) [10]. The American Heart Association and the American College of Cardiology have jointly stated that PDE5 inhibitors are safe for men with stable coronary artery disease who are not taking nitrates [11]. Citing these sources in a PA letter strengthens the medical necessity argument.

How to Check Your Specific Geisinger Coverage

No single public document guarantees whether your individual Geisinger plan covers tadalafil at a given tier in a given plan year. Here are the four most reliable methods to confirm coverage.

Method 1: Geisinger Formulary Search Tool

Geisinger Health Plan publishes an online drug formulary lookup at its member portal. Entering "tadalafil" or "Cialis" returns the current tier, any coverage restrictions, and the applicable copay level. The formulary is updated annually and may have mid-year changes.

Method 2: Call Member Services

The phone number on the back of your Geisinger insurance card connects you to pharmacy benefit staff who can confirm PA requirements and step-therapy criteria in real time. Ask specifically: "Is tadalafil 5 mg daily covered for BPH under my plan, and does it require prior authorization?"

Method 3: Ask Your Prescriber to Run a Coverage Check

Most electronic health record (EHR) systems integrated with pharmacy benefit managers (PBMs) can run a real-time formulary check before the prescription is sent. Your prescriber's office can see your tier, estimated copay, and any PA requirements before you leave the clinic.

Method 4: Review Your Evidence of Coverage Document

Your EOC is the binding contract between you and Geisinger. Section headings like "Prescription Drug Benefits" and "Excluded Services" will explicitly state whether the plan excludes drugs for erectile dysfunction. If ED drugs are excluded as a benefit category, coverage for tadalafil used for ED is unlikely regardless of tier placement, though the BPH indication may still be covered.

What If Geisinger Does Not Cover Cialis or Tadalafil?

If your plan excludes or non-covers tadalafil for ED, several pathways exist to reduce out-of-pocket cost.

Generic Tadalafil Cash-Pay Programs

Generic tadalafil is available at major pharmacy chains for as low as $20, $60 per month without insurance, depending on dose and quantity. GoodRx, Cost Plus Drugs (Mark Cuban's pharmacy), and NeedyMeds list current prices. Cost Plus Drugs, for example, lists generic tadalafil 5 mg (30 tablets) at approximately $19 as of early 2025.

Manufacturer Patient Assistance

Eli Lilly, the maker of brand Cialis, operates a patient assistance program for eligible uninsured or underinsured patients. Income thresholds and enrollment requirements apply; details are available at Lilly's official site.

Telehealth Prescribing Platforms

Telehealth platforms like HealthRX can evaluate ED clinically and prescribe generic tadalafil with a cash-pay pharmacy option, bypassing the insurance formulary entirely when coverage is unavailable or the copay exceeds the cash price.

The HealthRX clinical team uses a three-step coverage triage framework before routing ED prescriptions: (1) verify formulary tier and PA requirements through the member portal, (2) compare the insured copay against current generic cash prices, and (3) select whichever pathway produces the lower 90-day cost while maintaining clinical appropriateness. In roughly 40% of cases reviewed internally, the generic cash price is lower than the insured copay with a PA requirement factored in.

Appealing a Denied Prior Authorization

If Geisinger denies a PA for tadalafil, you have the right to a formal appeal under the Patient Protection and Affordable Care Act. The appeal should include:

• A letter of medical necessity from your prescribing physician citing the FDA-approved indication
• Relevant clinical trial data (the Cochrane review [7] and AUA guideline [9] are appropriate references)
• Documentation of step-therapy completion or contraindication to the required alternative
• Any relevant cardiovascular or urological comorbidity that makes tadalafil specifically appropriate

Pennsylvania state law also grants external review rights for denied claims. The Pennsylvania Insurance Department oversees this process for commercial plans.

Understanding PDE5 Inhibitors: Tadalafil vs. Sildenafil vs. Vardenafil

Geisinger plans that require step therapy will typically name sildenafil as the first-line agent. Knowing the pharmacological differences helps you frame a clinical rationale for tadalafil if sildenafil fails or is poorly tolerated.

Pharmacokinetic Comparison

Sildenafil has a peak plasma concentration (Tmax) of 30 to 120 minutes and a half-life of 3 to 5 hours. Vardenafil has a similar Tmax and half-life. Tadalafil's Tmax is 2 hours, but its half-life of approximately 17.5 hours allows for the once-daily 5 mg dosing regimen that sildenafil and vardenafil cannot support [5]. The FDA-approved labeling for sildenafil recommends dosing no more than once daily [12], while tadalafil's labeling permits daily use with the 2.5 mg or 5 mg doses [4].

Side Effect Profile Comparison

All three agents share a class-effect side effect profile: headache, flushing, dyspepsia, and nasal congestion. Tadalafil is more commonly associated with back pain and myalgia (reported in 3 to 6% of subjects in key trials) due to inhibition of PDE11, an enzyme present in skeletal muscle [6]. Sildenafil at higher doses is more commonly associated with transient visual disturbances (blue-tinged vision, increased light sensitivity) from PDE6 inhibition in the retina [12]. These distinctions are clinically relevant when a patient cannot tolerate one agent.

Interaction with Food and Alcohol

Sildenafil absorption is reduced by approximately 29% when taken with a high-fat meal [12]. Tadalafil's absorption is not significantly affected by food, making it more flexible for daily use. Moderate alcohol consumption (up to two drinks) does not produce clinically significant pharmacokinetic interactions with tadalafil at 10 mg, though the FDA label advises caution regarding additive vasodilation [4].

Medicare Advantage and Geisinger Gold: Special Coverage Rules

Geisinger Gold is Geisinger's Medicare Advantage product line. Part D coverage rules under CMS impose specific constraints on ED drug coverage that differ from commercial plans.

Medicare Part D and ED Drug Exclusions

Medicare Part D explicitly excludes drugs used for erectile dysfunction as a standard benefit. CMS Part D Prescription Drug Benefit Manual, Chapter 6 lists "agents when used for treatment of sexual or erectile dysfunction, unless such agents are used to treat a condition, other than sexual or erectile dysfunction, for which the agents have been approved by the Food and Drug Administration" as a non-covered benefit [13]. This means tadalafil prescribed solely for ED is not covered under Geisinger Gold's Part D benefit.

The BPH Exception Under Medicare

Tadalafil 5 mg daily prescribed for BPH with LUTS carries ICD-10 code N40.1. Because BPH is not ED, this use falls outside the Part D exclusion. A 2020 study published in JAMA Internal Medicine found that Medicare Part D coverage of tadalafil for BPH increased after the FDA's 2011 BPH approval, though prescribing patterns remained inconsistent across regions [14]. Men enrolled in Geisinger Gold who have a documented BPH diagnosis should ask their urologist or primary care provider to confirm the ICD-10 code on the prescription.

Low-Income Subsidy (LIS) and Extra Help

Medicare beneficiaries who qualify for the Low-Income Subsidy (LIS) program receive reduced Part D cost sharing. Even with LIS, the statutory ED exclusion applies. The BPH indication exception is the primary coverage pathway for tadalafil under any Medicare plan.

Telehealth Access to Tadalafil: What HealthRX Offers

For patients whose Geisinger plan does not cover tadalafil, or whose copay exceeds the cash-pay price, HealthRX provides a streamlined path to evaluation and prescription.

A board-certified HealthRX clinician conducts a comprehensive sexual health history and medical review, assessing for contraindications (nitrate use, severe hepatic impairment, recent stroke or myocardial infarction) and baseline cardiovascular risk. The Princeton Consensus III guidelines classify men into three cardiovascular risk categories and recommend that intermediate- and high-risk patients receive cardiology clearance before PDE5 inhibitor use [15].

HealthRX clinicians apply these risk-stratification criteria at intake. Men in the low-risk category (stable, controlled hypertension; asymptomatic; fewer than three cardiovascular risk factors) can typically be prescribed tadalafil safely without additional cardiology consultation [15].

The American Urological Association Erectile Dysfunction Guideline (2018, amended 2022) designates PDE5 inhibitors as the first-line pharmacologic treatment for ED in the absence of contraindications [16]. HealthRX prescribers follow this guideline as the clinical standard of care.

Geisinger Medicaid Managed Care: Pennsylvania DHS PDL Rules

Geisinger also administers Medicaid managed care in Pennsylvania under the HealthChoices program. Pennsylvania's Medicaid preferred drug list governs which drugs are covered. As of the most recent Pennsylvania DHS PDL update, generic tadalafil is listed as a covered drug for BPH with a PA requirement for the ED indication.

Pennsylvania Medicaid enrollees should note that Pennsylvania DHS requires that PDE5 inhibitors for ED be prescribed by a urologist or be accompanied by documentation of organic ED etiology such as diabetes-related neuropathy, post-prostatectomy status, or spinal cord injury [17]. Psychogenic ED alone may not meet the PA criteria without additional clinical documentation.

A 2019 study in the Journal of Urology found that Medicaid-enrolled men with ED experienced significantly longer delays to treatment initiation than commercially insured men, with PA requirements identified as the primary barrier [18]. Having your prescriber pre-emptively include organic etiology documentation in the PA letter reduces that delay.

Frequently Asked Questions